Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Avelox (moxifloxacin hydrochloride) tablet Clear all

Conditions: Prolonged QTc Interval, Pharmacokinetic
Interventions: 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy Volunteers
Interventions: Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pain
Interventions: VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Contraception
Interventions: ortho tricyclen, Trinessa; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: ACP-196, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: CXA-101/tazobactam, Moxifloxacin, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bacterial Pneumonia, Community-Acquired Infections
Interventions: Omadacycline, Moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Skin Diseases, Infectious
Interventions: PTK 0796, linezolid, moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more

Conditions: Healthy Volunteer
Interventions: TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: San Diego, California • Tacoma, Washington

Conditions: Healthy
Interventions: MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects
Interventions: GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors
Interventions: AZD6094 200 mg, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Aficamten, Aficamten-matching Placebo, Moxifloxacin; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cystic Fibrosis
Interventions: Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Bilastine, Bilastine & Ketoconazole, Moxifloxacin, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Subjects
Interventions: Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Autoimmune Diseases
Interventions: CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin; Drug
Lead sponsor: Connect Biopharma Australia Pty Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hialeah, Florida

Search by objective public record fields.

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Drug Interaction - Oral Contraceptive

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

A Phase 1 QT Study in Healthy Male Subjects

Study to Assess Cardiac Conduction of GSK1349572

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects